The U.S. Food and Drug Administration has approved a fast-acting diabetes drug called Afrezza for use by adults with Type 1 or Type 2 diabetes. The drug is inhaled into the lungs using a small inhaler ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through ...
The U.S. Food and Drug Administration today approved Afrezza Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting ...
The U.S. Food and Drug Administration's (FDA) delay in completing its review of MannKind Corp.'s ultra rapid-acting insulin therapy, called Afrezza, by the expected action date of January 16 has added ...
Afrezza may come in handy for certain diabetics who do not wish to get needled anymore because of their condition. MannKind Corp. Almost seven years since inhaled insulin appeared to have been an idea ...
Paris and Valencia, Calif. – February 3, 2015 – Sanofi and MannKind Corporation announced today that Afrezza ® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by ...
VALENCIA, Calif., Mar 15, 2010 (BUSINESS WIRE) -- MannKind Corporation /quotes/comstock/15*!mnkd/quotes/nls/mnkd (MNKD 10.48, -0.02, -0.19%) today announced that it ...
VALENCIA, Calif., April 1, 2014 – MannKind Corporation (Nasdaq: MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) ...
A major catalyst window opens for this biopharma stock with Q1 earnings due on May 6, and two key FDA decisions in May and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results